Chief Executive Officer at Burrill & Company
Early-stage companies are now embraced by buyers of new issues.
Biotech companies raise most money in 13 years.
Early-stage companies are finding alternatives to venture capital.
A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.
Collaborative R&D models coincide with new ways to fund translational research.
Better news about the global economy buoys life-sciences funding.
Greater emphasis on focus and efficiency for companies as market demands value in 2012.
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings